argenx (ARGX) vs. Adverum Biotechnologies (ADVM) Financial Comparison

argenx (NASDAQ:ARGX) and Adverum Biotechnologies (NASDAQ:ADVM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for argenx and Adverum Biotechnologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenx 0 1 7 0 2.88
Adverum Biotechnologies 0 4 1 0 2.20

argenx presently has a consensus price target of $138.71, suggesting a potential upside of 39.43%. Adverum Biotechnologies has a consensus price target of $6.88, suggesting a potential upside of 83.82%. Given Adverum Biotechnologies’ higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than argenx.

Risk & Volatility

argenx has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 3.83, indicating that its share price is 283% more volatile than the S&P 500.

Valuation and Earnings

This table compares argenx and Adverum Biotechnologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
argenx $44.74 million 71.54 -$31.73 million ($1.40) -71.06
Adverum Biotechnologies $1.85 million 126.74 -$56.14 million ($1.29) -2.90

argenx has higher revenue and earnings than Adverum Biotechnologies. argenx is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.


This table compares argenx and Adverum Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
argenx N/A N/A N/A
Adverum Biotechnologies -3,957.63% -30.61% -28.60%

Insider and Institutional Ownership

56.1% of argenx shares are held by institutional investors. Comparatively, 58.4% of Adverum Biotechnologies shares are held by institutional investors. 5.0% of Adverum Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with's FREE daily email newsletter.

Leave a Reply